Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
ackground: Evidence suggests that the serum myeloperoxidase level has a diagnostic and predictive role in patients with chronic heart failure (CHF). We evaluated the association between the serum myeloperoxidase level and the severity and prognosis of CHF.
Patients and Methods: In a prospective observational study, patients with CHF were evaluated. The myeloperoxidase serum level was measured at baseline by enzyme-linked immunosorbent assay. Transthoracic echocardiography was done at baseline and then after 6 months. History and duration of admission and also mortality were recorded during follow-up.
Results: Fifty patients at a mean age of 64.7±1.8 years (70% male) were evaluated. The mean serum myeloperoxidase level was 51.0±6.5mg/dL. Accordingly, the patients were classified into two groups of A and B with a serum myeloperoxidase level of less and more than 51mg/dl, respectively. No differences were found between the two groups in New York Heart Association functional class (NYHA III 20.5% vs.27.3%; p value=0.456), left ventricular ejection fraction (30.3±10.0 vs.29.8±10.1%; p value=0.873), systolic dysfunction (48.7% vs.54.5%; p value=0.500), or diastolic dysfunction (38.5% vs.63.6%; p value=0.127) neither at baseline, nor at 6 months’ follow-up. The serum myeloperoxidase level was not associated with admission history or mortality.
Conclusion: We found no significant association between the serum myeloperoxidase level and echocardiography parameters, admission history, or mortality in patients with CHF. Further studies with larger samples of patients are required in this regard.